Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective

Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle...

Descripción completa

Detalles Bibliográficos
Autores principales: Friesen, Chance S., Chan, Sherwin S., Wagner, Jonathan B., Hosey‐Cojocari, Chelsea, Csanaky, Iván L., Shakhnovich, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212707/
https://www.ncbi.nlm.nih.gov/pubmed/33476465
http://dx.doi.org/10.1111/cts.12952
_version_ 1783709689615220736
author Friesen, Chance S.
Chan, Sherwin S.
Wagner, Jonathan B.
Hosey‐Cojocari, Chelsea
Csanaky, Iván L.
Shakhnovich, Valentina
author_facet Friesen, Chance S.
Chan, Sherwin S.
Wagner, Jonathan B.
Hosey‐Cojocari, Chelsea
Csanaky, Iván L.
Shakhnovich, Valentina
author_sort Friesen, Chance S.
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle modification alone. Thus, children must be included in NAFLD pharmacology trials, which, to date, continue to focus primarily on adult populations. This commentary serves as a call to action.
format Online
Article
Text
id pubmed-8212707
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82127072021-06-25 Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective Friesen, Chance S. Chan, Sherwin S. Wagner, Jonathan B. Hosey‐Cojocari, Chelsea Csanaky, Iván L. Shakhnovich, Valentina Clin Transl Sci Perspectives Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle modification alone. Thus, children must be included in NAFLD pharmacology trials, which, to date, continue to focus primarily on adult populations. This commentary serves as a call to action. John Wiley and Sons Inc. 2021-01-21 2021-05 /pmc/articles/PMC8212707/ /pubmed/33476465 http://dx.doi.org/10.1111/cts.12952 Text en © 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Perspectives
Friesen, Chance S.
Chan, Sherwin S.
Wagner, Jonathan B.
Hosey‐Cojocari, Chelsea
Csanaky, Iván L.
Shakhnovich, Valentina
Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective
title Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective
title_full Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective
title_fullStr Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective
title_full_unstemmed Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective
title_short Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective
title_sort critical need for pharmacologic treatment options in nafld: a pediatric perspective
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212707/
https://www.ncbi.nlm.nih.gov/pubmed/33476465
http://dx.doi.org/10.1111/cts.12952
work_keys_str_mv AT friesenchances criticalneedforpharmacologictreatmentoptionsinnafldapediatricperspective
AT chansherwins criticalneedforpharmacologictreatmentoptionsinnafldapediatricperspective
AT wagnerjonathanb criticalneedforpharmacologictreatmentoptionsinnafldapediatricperspective
AT hoseycojocarichelsea criticalneedforpharmacologictreatmentoptionsinnafldapediatricperspective
AT csanakyivanl criticalneedforpharmacologictreatmentoptionsinnafldapediatricperspective
AT shakhnovichvalentina criticalneedforpharmacologictreatmentoptionsinnafldapediatricperspective

Ejemplares similares